Description: Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Home Page: cariboubio.com
CRBU Technical Analysis
2929 7th Street
Berkeley,
CA
94710
United States
Phone:
510 982 6030
Officers
| Name | Title |
|---|---|
| Dr. Rachel E. Haurwitz Ph.D. | Co-Founder, CEO, Pres & Director |
| Mr. Jason V. O'Byrne M.B.A. | Chief Financial Officer |
| Ms. Barbara G. McClung Esq., J.D. | Chief Legal Officer & Corp. Sec. |
| Mr. Daniel Poon | VP of Operations & Information Technology |
| Dr. Justin Skoble | VP of Technical Operations |
| Dr. Steven B. Kanner | Chief Scientific Officer |
| Ms. Amy Figueroa C.F.A. | VP of Investor Relations & Corp. Communications |
| Ms. Cindy Hayashi | VP of HR |
| Ms. Ruhi A. Khan M.B.A. | Chief Bus. Officer |
| Dr. Syed Ali-aamir Rizvi M.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5358 |
| Price-to-Sales TTM: | 37.0768 |
| IPO Date: | 2021-07-23 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |